Skip to main content
BC Innovations
Feature Story

DARPin-Pointing AAV

Novel engineered AAV vectors can target specific cell types

By Stephen Parmley, Senior Writer

Despite the recent gains in gene therapy, the main system for delivering genes - adeno-associated virus (AAV) vectors - still cannot target tissues of interest efficiently and leave other tissues untouched. A German group has engineered a chimeric form of AAV for customized targeting, based on DARPin antibody-like scaffolds that direct the vectors to cells expressing the antigen of interest. To move to the clinic, the team will need the capabilities and backing of their collaborators at Molecular Partners AG.

The strategy based on designed ankyrin repeat proteins (DARPins) is a departure from the more common approach of trying to solve the targeting problem by searching for rare serotypes of AAV with natural preferences for specific tissues.

Read Article

Today's Biotech & Pharma News

  • THE DISTILLERY brings you this week's most essential scientific findings in therapeutics, distilled by Innovations editors from a weekly review of more than 400 papers in 41 of the highest-impact journals in the fields of biotechnology, the life sciences and chemistry. The Distillery goes beyond the abstracts to explain the commercial relevance of featured research, including licensing status and companies working in the field, where applicable.

    This week in therapeutics includes important research findings on targets and compounds, grouped first by disease class and then alphabetically by indication.

    This week in techniques includes findings about research tools, disease models and manufacturing processes that have the potential to enable or improve all stages of drug discovery and development.

Subscribe Now
Free Trial